Gilead’s New Hepatitis C Drug Approved by FDA, Priced at $74,760

  • Epclusa is first treatment for all forms of the disease
  • Drug will mainly be used in patients with genotypes 2 and 3

Gilead's Hepatitis C Drug Approved by FDA

Gilead Sciences Inc.’s hepatitis C drug was approved by U.S. regulators for all forms of the viral disease, making it the first treatment with such a comprehensive label.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.